In Brief: IVD compliance policy
This article was originally published in The Gray Sheet
Executive Summary
IVD compliance policy: Availability of FDA's draft compliance policy guide on commercialization of in vitro diagnostics labeled for research or investigational use is slated to be announced in the Jan. 5 Federal Register. "Except in specified instances, FDA does not intend to initiate enforcement action for 18 to 30 months" after release of a final CPG against companies surreptitiously commercializing tests by labeling them for investigational or research use "provided the IVD manufacturers...take steps to obtain FDA approval," according to the announcement. Required steps "include undertaking, by six months" from publication of the final CPG, "any necessary clinical investigations or other studies."...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.